Anal Cancer
If it’s your first time on this website, please read the disclaimer section.
May 04 – May 11, 2026
Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This phase 3, randomized, double-blind trial (POD1UM-303/InterAACT-2) evaluated the efficacy of adding retifanlimab to carboplatin-paclitaxel as first-line treatment for 308 patients with advanced or metastatic squamous cell carcinoma of the anal canal. Results demonstrated a significant improvement in median overall survival (32.8 vs. 22.2 months; HR 0.75) and progression-free survival (HR 0.62) compared to chemotherapy alone. The combination therapy achieved a higher overall response rate of 56.5% versus 44.8% and maintained a consistent benefit across all analyzed subgroups without new safety concerns. These findings establish retifanlimab plus chemotherapy as a new reference standard of care for patients with inoperable, locally recurrent, or metastatic anal cancer.
10.1016/j.annonc.2026.04.016